Kymera Therapeutics Inc (NASDAQ: KYMR) on Monday, plunged -7.24% from the previous trading day, before settling in for the closing price of $40.62. Within the past 52 weeks, KYMR’s price has moved between $19.44 and $53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -26.36% over the past five years. The company achieved an average annual earnings per share of -11.85%. With a float of $58.31 million, this company’s outstanding shares have now reached $70.56 million.
Let’s look at the performance matrix of the company that is accounted for 188 employees. In terms of profitability, gross margin is 100.0%, operating margin of -472.5%, and the pretax margin is -409.07%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 16.89%, while institutional ownership is 91.13%. The most recent insider transaction that took place on Jun 30 ’25, was worth 13,955,348. In this transaction Director of this company bought 317,167 shares at a rate of $44.00, taking the stock ownership to the 2,798,795 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Director bought 655,500 for $44.00, making the entire transaction worth $28,842,000. This insider now owns 6,117,295 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.82 earnings per share (EPS) for the period topping the consensus outlook (set at -0.84) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.56% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 8.32 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 59.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.48, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -3.89 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (NASDAQ: KYMR) saw its 5-day average volume 0.79 million, a positive change from its year-to-date volume of 0.75 million. As of the previous 9 days, the stock’s Stochastic %D was 13.96%.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 59.16%, which indicates a significant increase from 10.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.54 in the past 14 days, which was lower than the 2.03 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.63, while its 200-day Moving Average is $39.09. Nevertheless, the first resistance level for the watch stands at $39.63 in the near term. At $41.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $43.07. If the price goes on to break the first support level at $36.19, it is likely to go to the next support level at $34.70. The third support level lies at $32.75 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
Market capitalization of the company is 2.64 billion based on 65,120K outstanding shares. Right now, sales total 47,070 K and income totals -223,860 K. The company made 22,100 K in profit during its latest quarter, and -65,580 K in sales during its previous quarter.
